Jump to Content Jump to Main Navigation

BPI21-006: Timing of NTRK Gene Fusion Testing and Treatment Modifications Following NTRK+ Status Among U.S. Oncologists Treating NTRK+ Patients

Authors: Landon Z. Marshall PharmD, PhD¹, Andrew J. Klink PhD¹, Abhishek Kavati PhD², Ruth Antoine MBA², Sibyl Anderson MD², and Bruce Feinberg MD¹

View More View Less

¹ Cardinal Health Specialty Solutions, Dublin, OH
| ² Bayer U.S. LLC, Whippany, NJ

Volume/Issue:: Volume 19: Issue 3.5

Online Publication Date:: 17 Mar 2021

DOI:: https://doi.org/10.6004/jnccn.2020.7757

Restricted access

All currencies in US Dollar

Corresponding Author: Landon Z. Marshall, PharmD, PhD

Print
Save
Cite
Email this content

Share Link

Copy this link, or click below to email it to a friend
Email this content
or copy the link directly:

https://jnccn.org/abstract/journals/jnccn/19/3.5/article-pBPI21-006.xml
The link was not copied. Your current browser may not support copying via this button.

Link copied successfully

Top

Copyright:: Copyright © 2021 by the National Comprehensive Cancer Network 2021

Article Category:: Abstract

Print Publication Date:: 20 Mar 2021

Online Publication Date:: 17 Mar 2021

Get Permissions

Similar articles in Google Scholar

	All Time	Past Year	Past 30 Days
Abstract Views	0	0	0
Full Text Views	187	187	11
PDF Downloads	197	197	8
EPUB Downloads	0	0	0